PPARγ agonists may also act as negative regulators of cancer growth by the interaction with the IGF system and its down-stream pathways, such as mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), and the mechanistic target of rapamycin (mTOR) pathways [10]. The gene discussed is PPARG; the disease is cancer.